EcoDrugPlus

Smoothened, Frizzled Class Receptor

Ensembl ID : ENSACCG00020002346
Gene Symbol: SMO
3 Cross references
204 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sodium Channel Epithelial 1 Subunit Alpha

Ensembl ID : ENSACCG00020015809
Gene Symbol: SCNN1A
3 Cross references
153 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sodium Channel Epithelial 1 Subunit Beta

Ensembl ID : ENSACCG00020011476
Gene Symbol: SCNN1B
1 Cross references
151 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sodium Channel Epithelial 1 Subunit Gamma

Ensembl ID : ENSACCG00020011384
Gene Symbol: SCNN1G
3 Cross references
155 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sodium Voltage-Gated Channel Alpha Subunit 3

Ensembl ID : ENSACCG00020010441
Gene Symbol: SCN3A
3 Cross references
133 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sodium Voltage-Gated Channel Alpha Subunit 4

Ensembl ID : ENSACCG00020016022
Gene Symbol: SCN4A
3 Cross references
190 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSACCG00020008274
Gene Symbol: SCN8A
1 Cross references
276 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Solute Carrier Family 10 Member 2

Ensembl ID : ENSACCG00020007405
Gene Symbol: SLC10A2
3 Cross references
211 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Solute Carrier Family 18 Member A2

Ensembl ID : ENSACCG00020007935
Gene Symbol: SLC18A2
1 Cross references
222 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Solute Carrier Family 22 Member 6-A-Like

Ensembl ID : ENSACCG00020012301
Gene Symbol: LOC115338341
2 Cross references
269 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Solute Carrier Family 5 Member 1

Ensembl ID : ENSACCG00020006653
Gene Symbol: SLC5A1
3 Cross references
250 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Solute Carrier Family 6 Member 1

Ensembl ID : ENSACCG00020010053
Gene Symbol: SLC6A1
3 Cross references
281 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).